Adventures in Capitalism: Outcry Over EpiPen Prices Hasn’t Made Them Lower
Sunday, June 4, 2017 - 16:11
in Mathematics & Economics
Mylan has an effective monopoly on a lifesaving product, which has allowed its leaders to see public outrage as a tax they must pay.